Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-16 04:47 • Investing.com Positive Axe Cap view: Selective

Johnson & Johnson experienced a mid-July stock pullback of approximately 2% following earnings results, but analysts view this as a buying opportunity. The company reported strong Q2 results with $25.31B in revenue (up 6.8% YOY), beat EPS expectations at $2.90, and raised full-year guidance. With a diversified portfolio, robust pipeline, upcoming orthopedics spin-off, and Dividend King status, the company is positioned for sustained growth despite talc litigation risks.

Axe note: Johnson & Johnson’s solid Q2 and raised guidance make its recent 2% drop an attractive entry point.

2026-07-16 04:29 • Investing.com Negative Axe Cap view: Neutral

Apple has rallied sharply toward record highs ahead of its Q3 2026 earnings report on July 30, driven by optimism about its AI strategy and ecosystem strength. However, skeptics question whether the stock's premium valuation is justified, citing concerns about unproven AI monetization, rising component costs forcing price increases across Mac and iPad lines, potential iPhone pricing pressures, and slowing China business growth. KeyBanc downgraded Apple to Underweight, warning that higher prices could reduce demand more than expected. The upcoming earnings report will be a critical test of whether Apple can demonstrate AI-driven growth and margin resilience.

Axe note: Apple’s rally on AI optimism faces scrutiny as cost pressures and China slowdown loom.

2026-07-16 03:19 • The Motley Fool Neutral Axe Cap view: Selective

Johnson & Johnson reported Q2 earnings that beat analyst estimates but disappointed investors, causing a 3% stock decline. While the company raised 2026 guidance and showed strong performance in key drugs like Darzalex and Tremfya, growth was modest compared to competitors. A concerning 2% decline in Abiomed heart pump sales, potentially linked to a negative UK study, raised concerns about the medical device segment.

Axe note: Johnson & Johnson beat earnings but still fell short of investor expectations, leaving a cautious aftertaste.